奥司他韦分布于中耳和鼻窦的流感病毒复制部位。 - Suppr

Suppr

超能文献

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.

作者信息

Kurowski Michael, Oo Charles, Wiltshire Hugh, Barrett Joanne

机构信息

Therapia GmbH, c/o Auguste-Viktoria-Krankenhaus, Berlin, Germany.

出版信息

Clin Drug Investig. 2004;24(1):49-53. doi: 10.2165/00044011-200424010-00006.

DOI:10.2165/00044011-200424010-00006

PMID:17516690

Abstract

摘要

相似文献

Oseltamivir distributes to influenza virus replication sites in the middle ear and sinuses.奥司他韦分布于中耳和鼻窦的流感病毒复制部位。

Clin Drug Investig. 2004;24(1):49-53. doi: 10.2165/00044011-200424010-00006.

Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.韩国分离的抗奥司他韦的大流行（H1N1）2009 流感病毒的哺乳动物发病机制

Virus Res. 2014 Jun 24;185:41-6. doi: 10.1016/j.virusres.2014.03.014. Epub 2014 Mar 19.

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.RWJ-270201、扎那米韦和奥司他韦对H5N1、H9N2及其他禽流感病毒的疗效比较。

Antimicrob Agents Chemother. 2001 Oct;45(10):2723-32. doi: 10.1128/AAC.45.10.2723-2732.2001.

Pomegranate (Punica granatum) purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir.石榴（Punica granatum）纯化多酚提取物抑制流感病毒，并与奥司他韦具有协同作用。

Phytomedicine. 2009 Dec;16(12):1127-36. doi: 10.1016/j.phymed.2009.06.002. Epub 2009 Jul 7.

Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.低剂量口服奥司他韦和金刚烷胺联合化学预防小鼠甲型流感病毒感染

J Chemother. 2007 Jun;19(3):295-303. doi: 10.1179/joc.2007.19.3.295.

The effects of neuraminidase inhibitors on the release of oseltamivir-sensitive and oseltamivir-resistant influenza viruses from primary cultures of human tracheal epithelium.神经氨酸酶抑制剂对人气管上皮原代培养物中释放的奥司他韦敏感型和奥司他韦耐药型流感病毒的影响。

J Med Virol. 2015 Jan;87(1):25-34. doi: 10.1002/jmv.23974. Epub 2014 May 16.

Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine.用奥司他韦、利巴韦林和硝唑尼特治疗小鼠中甘露聚糖增强的乙型流感病毒感染。

Antivir Chem Chemother. 2004 Sep;15(5):261-8. doi: 10.1177/095632020401500505.

Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro.碳环类似物对流感 A 病毒的体外复制抑制活性：奥司他韦相关研究。

Antiviral Res. 2011 Jun;90(3):160-3. doi: 10.1016/j.antiviral.2011.03.180. Epub 2011 Apr 2.

Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro.MEK 抑制剂与奥司他韦联用在体外流感 A 病毒感染后具有协同抗病毒作用。

Antiviral Res. 2013 May;98(2):319-24. doi: 10.1016/j.antiviral.2013.03.006. Epub 2013 Mar 20.

In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201.环戊烷神经氨酸酶抑制剂RJW-270201的体内抗流感病毒作用

Antimicrob Agents Chemother. 2001 Mar;45(3):749-57. doi: 10.1128/AAC.45.3.749-757.2001.

引用本文的文献

A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans.磷酸奥司他韦及其羧酸盐代谢物在大鼠和人类中的生理药代动力学模型。

ADMET DMPK. 2019 Feb 23;7(1):22-43. doi: 10.5599/admet.628. eCollection 2019.

A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses.神经氨酸酶中一种新的I221L替代导致乙型流感病毒对奥司他韦产生高水平耐药。

J Infect Dis. 2014 Oct 15;210(8):1260-9. doi: 10.1093/infdis/jiu244. Epub 2014 May 3.

Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial.奥司他韦耐药季节性甲型 H1N1 流感病毒感染患者的临床和病毒学结局：一项临床试验的结果。

Influenza Other Respir Viruses. 2012 May;6(3):153-8. doi: 10.1111/j.1750-2659.2011.00312.x. Epub 2011 Nov 26.

Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.奥司他韦在季节性流感、大流行流感和禽流感中的应用：10 年临床经验综合评述。

Adv Ther. 2011 Nov;28(11):927-59. doi: 10.1007/s12325-011-0072-7. Epub 2011 Nov 1.

Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.奥司他韦在季节性、禽流感 H5N1 和大流行 2009 年 A/H1N1 流感中的药代动力学和药效学特征。

Clin Pharmacokinet. 2010 Nov;49(11):741-65. doi: 10.2165/11534730-000000000-00000.

Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.奥司他韦的药代动力学：一种用于治疗和预防不同人群流感的口服抗病毒药物。

J Antimicrob Chemother. 2010 Apr;65 Suppl 2(Suppl 2):ii5-ii10. doi: 10.1093/jac/dkq015.

Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.奥司他韦及其羧酸酯在中枢神经系统中的非临床药代动力学。

Antimicrob Agents Chemother. 2009 Nov;53(11):4753-61. doi: 10.1128/AAC.01541-08. Epub 2009 Aug 31.

Antivirals for the treatment and prevention of epidemic and pandemic influenza.用于治疗和预防流行性和大流行性流感的抗病毒药物。

Influenza Other Respir Viruses. 2007 Jan;1(1):27-34. doi: 10.1111/j.1750-2659.2006.00006.x.

Safety and pharmacology of oseltamivir in clinical use.临床使用中奥司他韦的安全性与药理学

Drug Saf. 2003;26(11):787-801. doi: 10.2165/00002018-200326110-00004.

本文引用的文献

In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors.流感神经氨酸酶抑制剂的体外和体内疗效

Curr Opin Infect Dis. 1998 Dec;11(6):727-32. doi: 10.1097/00001432-199812000-00013.

Oral oseltamivir treatment of influenza in children.口服奥司他韦治疗儿童流感。

Pediatr Infect Dis J. 2001 Feb;20(2):127-33. doi: 10.1097/00006454-200102000-00002.

Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom.英国基于人群的流感发病率、危险因素、临床并发症及药物使用情况研究。

Eur J Clin Microbiol Infect Dis. 2000 Nov;19(11):834-42. doi: 10.1007/s100960000376.

Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.开发一种高效液相色谱-质谱分析法，用于特异性和灵敏地定量测定抗流感药物Ro 64-0802及其前药奥司他韦在人和动物血浆及尿液中的含量。

J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):373-88. doi: 10.1016/s0378-4347(00)00300-5.

Influenza A virus infection of human middle ear cells in vitro.

Laryngoscope. 2000 Oct;110(10 Pt 1):1739-44. doi: 10.1097/00005537-200010000-00034.

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.奥司他韦治疗急性流感的疗效与安全性：一项随机对照试验。神经氨酸酶抑制剂流感治疗研究组。

Lancet. 2000 May 27;355(9218):1845-50. doi: 10.1016/s0140-6736(00)02288-1.

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.口服神经氨酸酶抑制剂奥司他韦治疗急性流感的疗效与安全性：一项随机对照试验。美国口服神经氨酸酶研究组。

JAMA. 2000 Feb 23;283(8):1016-24. doi: 10.1001/jama.283.8.1016.

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.前体药物奥司他韦及其活性代谢产物Ro 64-0802的临床药代动力学

Clin Pharmacokinet. 1999 Dec;37(6):471-84. doi: 10.2165/00003088-199937060-00003.

Prevalence of various respiratory viruses in the middle ear during acute otitis media.急性中耳炎期间中耳内各种呼吸道病毒的流行情况。

N Engl J Med. 1999 Jan 28;340(4):260-4. doi: 10.1056/NEJM199901283400402.

Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection.口服流感病毒神经氨酸酶抑制剂GS 4071的前体药物可保护小鼠和雪貂免受流感感染。

Antimicrob Agents Chemother. 1998 Mar;42(3):640-6. doi: 10.1128/AAC.42.3.640.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验